Методичні вказівки для проведення практичних занять і організації самостійної роботи з навчальної дисципліни «Управління нерухомим майном» (для студентів 4 курсу денної і заочної форм навчання напряму підготовки 6.080101 – Геодезія, картографія та землеустрій).

Table S2. Week-4 simeprevir pharmacokinetic parameters after administration in (a) Panels 1–3 and (b) Panel 4. (DOCX 15 kb

Liver and gallbladder & intestines time-activity curves of [¹⁸F]FCA in control, rifampicin and bosentan treated FVB-mice (n = 3 per group).

<p>Uptake of [¹⁸F]FCA is expressed as % injected dose and normalized for a 20 g mouse. Values are expressed as mean ± SD.</p

Time-activity curves of [¹⁸F]FCA in liver and gallbladder & intestines of wild-type FVB-mice (n = 3).

<p>Uptake of [¹⁸F]FCA is expressed as % injected dose and normalized for a 20 g mouse. Values are expressed as mean ± SD.</p

Metrics of [¹⁸F]FCA in liver and gallbladder & intestines in wild-type FVB-mice (n = 3).

<p>Values are expressed as mean ± SD.</p

Maximum intensity projection PET/CT images of [¹⁸F]FCA in 2 wild-type FVB-mice at different time points.

<p>Images were generated in AMIDE Medical Image Data Examiner software; slice thickness: 12 mm. In the early phase (3–20 minutes post-injection), the liver, gallbladder and intestines are visible. In a later phase (20–60 minutes post-injection), all radioactivity is excreted from the liver to the gallbladder and intestines. The late phase PET/CT images (6 hours post-injection) show that [¹⁸F]FCA remains present only in gallbladder and intestines: visual analysis of all images showed no uptake in other organs than liver, gallbladder and intestines.</p

Radiosynthesis of 3β-[¹⁸F]Fluoro-7α,12α-Diacetoxy-5β-Cholanic Acid Methyl Ester ([¹⁸F]FAcCAME) and subsequent deprotection to 3β-[¹⁸F]Fluorocholic Acid ([¹⁸F]FCA).

<p><i>i</i>: [¹⁸F]Fluoride/K₂₂₂-K₂CO₃; DMSO; 120°C; 20 min. <i>ii</i>: 1 M NaOH; 120°C; 10 min.</p

FCA concentration dependent inhibition of [³H]Taurocholate ([³H]TC) and [³H]Estradiol-17β-Glucuronide ([³H]EbG) in BSEP and MRP2 vesicles respectively.

<p>Values are expressed as mean ± SD (n = 3).</p

Time-activity curve metrics of [¹⁸F]FCA in control, rifampicin and bosentan treated animals (n = 3 per group).

<p>Values are expressed as mean ± SD. *: significant difference compared to control group. A p-value of 0.05 was considered significant.</p

General parameters.

<p><b>A</b>: Liver/ bodyweight ratios for all groups <b>B</b>: Prevalence of cholangioma and hepatocellular lesions, showing percentage of mice showing one or more cholangioma or (premalignant) HCC lesions <b>C:</b> Representative images of Sirius red and reticulin staining showing cholangioma lesions in all DMOG groups except for PBS control after 22 weeks, and HCC lesions in all DEN groups except for the Int. DMOG group. Scale bars: 200μm, *: p<0,05; **p<0,01. DMOG: dimethyloxaloylglycine; DEN: diethylnitrosamine</p

mRNA expression of Notch and metastasis markers.

<p><b>A:</b> mRNA expression of Notch and metastasis markers after early and Int. DMOG <b>B:</b> mRNA expression of Notch and metastasis markers after Adv. DMOG in DEN induced hepatocellular carcinoma. *p<0,05; **p<0,01, ## p<0,01 compared to all other groups. DMOG: dimethyloxaloylglycine; DEN: diethylnitrosamine</p